Saltar al contenido
Merck

An update on the use of ophthalmic ketorolac tromethamine 0.4%.

Expert opinion on pharmacotherapy (2005-12-24)
Henry D Perry, Eric D Donnenfeld
RESUMEN

Ketorolac tromethamine 0.4% ophthalmic solution, a recent reformulation of the original ketorolac tromethamine 0.5% solution, is indicated for the reduction of ocular pain and burning/stinging following cataract and refractive surgery. Studies have demonstrated that ketorolac tromethamine 0.4% has equivalent efficacy to ketorolac tromethamine 0.5% in reducing postsurgical inflammation and controlling pain. Several studies have demonstrated that, as well as reducing pain and ocular inflammation, ketorolac tromethamine 0.4% effectively treats cystoid macular oedema, inhibits miosis and may prevent cystoid macular oedema when used both pre- and postoperatively. Ketorolac tromethamine 0.4% is a versatile agent and is effective when used as either monotherapy or as an adjunct therapy to steroids.

MATERIALES
Número de producto
Marca
Descripción del producto

Supelco
Ketorolac Tromethamine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ketorolac tris salt, ≥99%, crystalline
Ketorolac trometamol, European Pharmacopoeia (EP) Reference Standard
Ketorolac trometamol for peak identification, European Pharmacopoeia (EP) Reference Standard